RAC1 and diabetes mellitus: Our results suggest that for the treatment of PDAC and PDAC-related diabetes, therapeutically modulating the RAC1b:RAC1 ratio may be feasible in both instances, prevention of dedifferentiation/eradication of CSCs (through an increase) or enhancing dedifferentiation and stem cell features (through a decrease) for subsequent deTD therapy.